Key facts
- Sim&Cure’s last known valuation is $48.7M (Nov 2025).
- It has raised $21.1M; the latest was Equity Crowdfunding ($840K) in Apr 2025.
- Notable investors include Elaia Partners, IRDI Capital Investissement, SWEN Capital Partners, Sofilaro, Alexis Frentz — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Sim&Cure
- ·The full record, as it builds
Funding rounds
No funding rounds for Sim&Cure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sim&Cure
Developer of a patient-specific device designed to secure the treatment of a cerebral aneurysm. The company's device is fast and has optimal sizing, virtually evaluates the final position of different sizes and shapes of intracranial implants and secures the treatment, enabling neurologists to treat patients with neurovascular disorders.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2013
- Employees
- 65
- Website
- sim-and-cure.com/
- Ownership
- Privately Held (backing)
Sim&Cure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sim&Cure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sim&Cure in its N-PORT filings yet. We sweep new filings monthly.